Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HMBS and GAPDH were identified as the optimal reference genes for normalizing gene expression data between paired tumoral and adjacent non-tumoral tissues derived from patients with HCC.
|
19036168 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time PCR demonstrated that the mean ratio of FGFR3 mRNA to glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA in HCC tissue was 0.250, whereas the ratio in non-neoplastic liver tissue was 0.014.
|
16149130 |
2005 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The involvement of GAPDH in several hepatocarcinogenic mechanisms (e.g. viral hepatitis, metabolic alterations) and its sensitivity to a new class of prospective anticancer agents prompted us to review the current understanding of the therapeutic potential of targeting GAPDH in HCC.
|
22964488 |
2012 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The differentially expressed genes (DEGs) in HCC samples were screened using the ΔΔCt method with the homogenized internal GAPDH.
|
26045814 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relative Heparanase mRNA expression level (Heparanase: glyceraldehyde-3-phosphate dehydrogenase ratio) in hepatocellular carcinoma was lower than that in noncancerous tissue (P < 0.05).
|
23771368 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
When stably transfected and expressed in 3T3-F442A preadipocytes and H35 hepatoma cells, the intact human GAPDH gene is induced 10-fold by insulin in 3T3-F442A adipocytes and 3-fold by insulin in H35 hepatoma lines, which is similar to the induction obtained with the endogenous gene.
|
2839830 |
1988 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we show that transcriptional activity is reduced by deletion of the nucleotides from -181 to -144 (relative to the transcriptional start site) in the promoter of human GAPDH gene, both in CHO (derived from Chinese hamster ovary) and HepG2 (derived from human hepatoma) cells.
|
9378702 |
1997 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining for GAPDH was investigated in 137 HCC tissue samples from our center.
|
31239764 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR demonstrated that the expression of relative HMGB1 mRNA (HMGB1/GAPDH) was 0.854 ± 0.172; the highest in the tissue of HCC, significantly up-regulated compared with that of 0.527 ± 0.155 in LAT and of 0.405 ± 0.087 in normal liver tissues (P < 0.001).
|
21953322 |
2012 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma GAPDH mRNA concentrations in HCC patients were significantly higher than those in healthy individuals, both with or without filtration (P <0.0 5 for filtered plasma samples; P <0.005 for unfiltered plasma samples).
|
12142376 |
2002 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of KiSS-1, hOT7T175 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNAs (mRNAs) were analyzed quantitatively by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in 60 surgically resected HCCs.
|
12898236 |
2003 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28s-ribosomal RNA gene expression in human hepatocellular carcinoma.
|
8666326 |
1996 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of these 6 genes relative to that of GAPDH was measured by QRT-PCR in 82 HCCs.
|
18202799 |
2008 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results showed that <i>TFG</i> and <i>SFRS4</i> are among the most reliable reference genes, and <i>ACTB</i> ranks third and acts quite well as a classical choice, whereas <i>GAPDH, HPRT1</i> and <i>TUBB</i> are not proper reference genes in qRT-PCR assays among the HCC cell lines.
|
29180379 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ALDO: aldolase, fructose-bisphosphate; CQ: chloroquine; DLAT/PDCE2: dihydrolipoamide S-acetyltransferase; EMT: epithelial-mesenchymal transition; ENO: enolase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLS/GLS1: glutaminase; GLUL/GS: glutamine-ammonia ligase; GPI/PGI: glucose-6-phosphate isomerase; HCC: hepatocellular carcinoma; HGF: hepatocyte growth factor; HK: hexokinase; LDH: lactate dehydrogenase; LIHC: liver hepatocellular carcinoma; LIR: LC3-interacting region; PDH: pyruvate dehydrogenase; PDHA1: pyruvate dehydrogenase E1 alpha 1 subunit; PDHX: pyruvate dehydrogenase complex component X; PFK: phosphofructokinase; PK: pyruvate kinase; RTK: receptor tyrosine kinase; TCGA: The Cancer Genome Atlas.
|
30786811 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma.
|
16767786 |
2006 |